1. P.016 Reduction in migraine-associated burden over 24 weeks of treatment with eptinezumab in patients with chronic migraine. (June 2022) Authors: McAllister, P; Kudrow, D; Cady, R; Hirman, J; Ettrup, A; Minhas, S Journal: Canadian journal of neurological sciences Issue: Volume 49(2022)Supplement 1 Page Start: S11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P.017 Optimization of acute treatment and headache-related impact following eptinezumab initiated during a migraine attack: post hoc analysis of the RELIEF study. (June 2022) Authors: Buse, DC; Lipton, RB; Ettrup, A; Josiassen, MK; Lindsten, A; Cady, R; Omeragic, A; Duong, A Journal: Canadian journal of neurological sciences Issue: Volume 49(2022)Supplement 1 Page Start: S12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P.027 Efficacy and Safety of Eptinezumab Initiated During a Migraine Attack: Results from the RELIEF Study. (November 2021) Authors: Winner, PK; McAllister, P; Chakhava, G; Ailani, J; Mehta, L; Ettrup, A; Krog Josiassen, M; Lindsten, A; Bougie, JK; Cady, R Journal: Canadian journal of neurological sciences Issue: Volume 48(2021)Supplement S3 Page Start: S27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗